Pharmacotherapy of Musculoskeletal Conditions in the Elderly

farmakoloji-11-2-2023-wos

Yeşim GÖKÇE KUTSALa , Tolga Reşat AYDOSb

aHacettepe University Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Ankara, Türkiye
bBaşkent University Faculty of Medicine, Department of Medical Pharmacology, Ankara, Türkiye

ABSTRACT
Musculoskeletal diseases negatively affect the quality of life of elderly individuals,and well-being in aging societies and continues to pose problems not only in medical, but also in social and economic terms as well. Physicians should be more alert during a prescription to older patients, consider the pharmacokinetic and pharmacodynamic changes associated with aging and monitor their health status with individual attention. The use of drugs for the musculoskeletal system, such as paracetamol, opioids, tramadol, duloxetine, drugs use in neuropathic pain, myorelaxans, drugs use in osteoporosis, nonsteroidal anti-inflammatory drugs, glucocorticoids and disease-modifying antirheumatic drugs requires an individual-based treatment protocol. Patients should be carefully evaluated for comorbidities, polypharmacy and major organ functionality before starting the medication and it is necessary to closely monitor adverse effects during the treatment.
Keywords: Musculoskeletal diseases; drug therapy; elderly

Referanslar

  1. Kutsal Y, Kabaroglu C, Aslan D. Biogerontology in Turkey: a brief report. Biogerontology. 2011;12(1):83-6. [Crossref]  [PubMed]
  2. Gokce Kutsal Y. Geriatric Syndromes. International Journal on Ageing in Developing Countries, 2019;4(1):41-56.
  3. Benlidayı İC, Kutsal YG. A Spiral of Cumulative Problems: Gerontorheumatology.Turkish Journal of Geriatrics 2021;24(4):441-50. [Crossref]
  4. Minetto MA, Giannini A, McConnell R, Busso C, Torre G, Massazza G. Common Musculoskeletal Disorders in the Elderly: The Star Triad. J Clin Med. 2020;23;9(4):1216. [Crossref]  [PubMed]  [PMC]
  5. Sera LC, McPherson ML. Pharmacokinetics and pharmacodynamic changes associated with aging and implications for drug therapy. Clin Geriatr Med.2012;28:273-86. [Crossref]  [PubMed]
  6. Drenth-van Maanen AC, Wilting I, Jansen PAF. Prescribing medicines to older people-How to consider the impact of ageing on human organ and body functions. Br J Clin Pharmacol.2020;86(10):1921-30. [Crossref]  [PubMed]  [PMC]
  7. Turnheim K. Drug dosage in the elderly. Is it rational? Drugs Aging.1998;13 (5):357-79. [Crossref]  [PubMed]
  8. Rodrigues DA, Herdeiro MT, Figueiras A, Coutinho P, Roque F. Elderly and Polypharmacy: Physiological and Cognitive Changes. In: Sara Palermo, ed. Frailty in the Elderly - Understanding and Managing Complexity. IntechOpen; 2020. p.1-14. [Crossref]
  9. Gökçe Kutsal Y. Yaşlılıkta Anti-Romatizmal İlaçların Kullanımı. Bodur H, Ataman Ş, editörler. Romatoloji e-Kitap 2021. [İnternet]: [Link]
  10. Rizzoli R, Branco J, Brandi ML, Boonen S, Bruyère O, Cacoub P, et al. Management of osteoporosis of the oldest old. Osteoporos Int. 2014;25(11):2507-29. [Crossref]  [PubMed]
  11. Hagino H, Ito M, Hashimoto J, Yamamoto M, Endo K, Katsumata K, et al. Monthly oral ibandronate 100 mg is as effective as monthly intravenous ibandronate 1 mg in patients with various pathologies in the MOVEST study. J Bone Miner Metab. 2018;36(3):336-43. [Crossref]  [PubMed]
  12. Curtis JR, Safford MM. Management of osteoporosis among the elderly with other chronic medical conditions. Drugs Aging. 2012;29(7):549-64. [Crossref]  [PubMed]  [PMC]
  13. Silverman S, Agodoa I, Kruse M, Parthan A, Orwoll E. Denosumab for elderly men with osteoporosis: a cost-effectiveness analysis from the US Payer Perspective. J Osteoporos. 2015;2015: 627631. [Crossref]  [PubMed]  [PMC]
  14. Niimi R, Kono T, Nishihara A, Hasegawa M, Matsumine A, Kono T, et al. Usefulness of daily teriparatide treatment in elderly patients over 80 years of age. Osteoporos Int.2016;27(5):1869-74. [Crossref]  [PubMed]
  15. Coskun Benlidayi I, Gokce Kutsal Y. Antirheumatic drugs in older adults and polypharmacy issues. Z Gerontol Geriat 2022;55,507-12. [Crossref]  [PubMed]
  16. Yıldız V, Özdemir O, Gökçe Kutsal Y. Medication nonadherence in elderly and recommendations to imrove adherence. Turkish Journal of Geriatrics. 2017;20:344-50.
  17. Gökçe Kutsal Y, Eyigör S, Karahan S, Günaydın R, İrdesel J, Sarıdoğan M, et al. Incorporating patient preferences into osteoarthritis treatment. Arch Rheumatol 2021;36(4):577-86. [Crossref]  [PubMed]  [PMC]
  18. Gökçe Kutsal Y. Controversial issues related to drug treatment in the elderly. Turkish Journal of Geriatrics. 2022;25 (1):1-12. [Crossref]